ACTRN12621000851864
Recruiting
Phase 2
Investigating the effect of intralesional triamcinolone acetonide on the size of cutaneous squamous cell carcinomas in elderly adults with squamous cell carcinoma of the lower limbs
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Cutaneous squamous cell carcinoma
- Sponsor
- Sydney Local Health District
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Aged 70 years or older
- •2\.Lower limbs clinically deemed to be high risk for wound healing (including but not limited to diabetes mellitus; chronic venous disease changes affecting the lower limb; lipodermatosclerosis; history of lower limb cellulitis; history of poor wound healing on lower legs; lower limb oedema)
- •3\.Potential participants must have at least one lesion on the legs clinically consistent with low\-grade SCC. Biopsy would be taken (3mm punch) as per standard clinical practice. If confirmed to be SCC, the tumour(s) must be histologically proven primary low\-grade cutaneous SCC of the lower limb
- •4\. Low\-grade tumours must have zero high\-risk factors as per Brigham and Women’s Hospital Tumour Staging system for cSCC. These risk factors include:
- •\- Diameter greater than or equal to 2cm
- •\- Poorly\-differentiated histology
- •\- Perineural invasion greater than or equal to 0\.1mm
- •\- Tumour invasion beyond fat
- •5\.Patient agreeable to delay in surgical excision. It should be noted that the 5 week duration of the trial falls within usual time to excision of well\-differentiated cSCC on the lower limbs in the clinics which is 1\-2 months.
- •6\.Willingness and ability to provide informed consent and willingness to participate and comply with the study requirements.
Exclusion Criteria
- •1\. Histologically proven cSCC that are moderately or poorly differentiated
- •2\. Unable to follow up for the duration of the study due to frailty, geographical or social reasons
- •3\. Known contraindication to injection of triamcinolone acetonide (such as hypersensitivity to ingredients).
- •4\. Patient prefers surgical excision
- •5\. Patient undertaking other treatment for the lesion or lesions (such as field treatments, radiotherapy, photodynamic therapy)
- •6\. Immune suppression (including transplant recipients, chronic haematological malignancies, immune\-suppressive medications for autoimmune disorders)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
To assess the outcome of Intralesional triamcinolone acetonide with 5 -fluorouracil in the treatment of keloidsCTRI/2023/02/049632SURYA T
Recruiting
Phase 4
Effects of intraarticular infiltration in rheumatoid arthritis women´s kneesC05.550.114.154Rheumatoid ArthritisRBR-4g4sk8niversidade Estadual Paulista - UNESP
Not yet recruiting
Phase 3
Comparison of a 1.25 mg/ml intralesional triamcinolone acetonide with combination of a 1.25 mg/ml intralesional triamcinolone acetonide and comedone extraction in healing of inflammatory acnes in moderate-to-severe adult acne: a randomized, split-face controlled trialmoderate to severe acneInflammatory acne, intralesional triamcinolone acetatonide, intralesional corticosteroidTCTR20210924008Dermatology unit, department of internal medicine, Chulalongkorn university40
Not yet recruiting
Not Applicable
To assess and compare the intralesional traiamcinolone injection by ultrasound guided vs palpation method in the management of acute plantar fasciitisCTRI/2021/08/035846department of anesthesiology and critical care pain medicine
Completed
Phase 3
Comparison of triamcinolone and dextrose prolotherapy in patients with knee osteoarthritisKnee osteoarthritis.M17GonarthrosIRCT20170311033000N4Shahid Beheshti University of Medical Sciences40